drugset / Trial / NCT00688636

Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery

NCT00688636

Phase 4 Completed 24 enrolled University of Pittsburgh Centocor, Inc. · collab
RandomizedSingle-groupDouble-blindPrevention

Summary

A randomized, placebo-controlled pilot study to determine endoscopic recurrence of Crohn's disease 12 months after curative, resective ileal or ileocolonic surgery in patients receiving post-operative infliximab or placebo

Timeline

Start
2005-01
Primary completion
2008-08
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Infliximab Monoclonal antibody 5 mg/kg Intravenous

Indications